D.A. Davidson & Co. Recursion Pharmaceuticals, Inc. Transaction History
D.A. Davidson & Co.
- $12.2 Billion
- Q1 2025
A detailed history of D.A. Davidson & Co. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 107,432 shares of RXRX stock, worth $449,065. This represents 0.0% of its overall portfolio holdings.
Number of Shares
107,432
Previous 15,992
571.79%
Holding current value
$449,065
Previous $108,000
425.93%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RXRX
# of Institutions
365Shares Held
286MCall Options Held
3.28MPut Options Held
3.16M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl34.8MShares$146 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.3MShares$135 Million0.0% of portfolio
-
Baillie Gifford & CO24.4MShares$102 Million0.12% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$72.4 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$61.3 Million0.27% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $754M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...